Home > Offer to Sell > Pharmaceuticals and Biochemicals > Antianaphylaxis(antihistamines) and antidotes > Tofacitinib Citrate
Tofacitinib Citrate
Inquiry
Post Date: | Oct 06,2013 |
Expiry Date: | Oct 06,2014 |
Detailed Description: |
Cas No. :540737-29-9
Specs:Min purity 99%-inhouse specs Tofacitinib Citrate is a drug of the janus kinase (JAK) inhibitor class. It is currently approved for the treatment of rheumatoid arthritis (RA) in the United States and is being studied for treatment of psoriasis, inflammatory bowel disease, and other immunological diseases, as well as for the prevention of organ transplant rejection. |
CAS Registry Number: | 540737-29-9 |
Synonyms: | ;Tofacitinib citrate;1-Piperidinepropanenitrile, 4-Methyl-3-(Methyl-7H-Pyrrolo[2,3-D]Pyrimidin-4-Ylamino)-Beta-Oxo-, (3R,4R)-, 2-Hydroxy-1,2,3-Propanetricarboxylate (1:1);1-PIPERIDINEPROPANENITRILE,4-METHYL-3-(METHYL-7H-PYRROLO[2,3-D]PYRIMIDIN-4-YLAMINO)-BETA-OXO-,(3R,4R)-,2-HYDROXY-1,2,3-PROPANETRICARBOXYLATE(1:1);Tasocitinib citrate;(3R,4R)-1-(Cyanoacetyl)-4-methyl-N-methyl-N-1H-pyrrolo[2,3-d]pyrimidin-4-yl-3-piperidinamine 2-hydroxy-1,2,3-propanetricarboxylate;CP 690500-10;CP 690550-10;(3R,4R)-4-Methyl-3-(methyl-7H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-beta-oxo-1-piperidinepropanenitrile 2-Hydroxy-1,2,3-propanetricarboxylate;Tofacitnib Citrate; |
Molecular Formula: | C16H20N6O·C6H8O7 |
Molecular Weight: | 504.497 |
Molecular Structure: |
Company: | Stereokem [ United States ] |
Contact: | Sundar |
Tel: | +1-415-290-0331 |
Fax: | |
Email: | gideon@stereokem.com |
-
Disclaimer statement:The information and data included above have been realized by the enterprises and compiled by the staff, and are subject to change without notice to you. The Chemnet makes no warranties or representations whatsoever regarding the facticity, accuracy and validity of such information and data. In order to ensure your interest, we suggest you chose the products posted by our gold suppliers or VIP members.